Results 111 to 120 of about 402,161 (308)

Chronic Myeloid Leukemia in 2007 [PDF]

open access: yesJournal of Managed Care Pharmacy, 2007
Chronic myeloid leukemia (CML), a hematopoietic stem cell cancer representing 15-20% of adult leukemias, is discussed. Epidemiology, staging biology, and monitoring techniques are reviewed.CML is a myeloproliferative disorder that affects all lineages of hematopoiesis.
openaire   +3 more sources

Gut Mycobiota‐Associated Tryptophan Catabolites Protect Against Metabolic Dysfunction‐Associated Steatotic Liver Disease

open access: yesAdvanced Science, EarlyView.
ABSTRACT Accumulating evidence suggests that the intestinal microbiota participates in the progression of metabolic dysfunction‐associated steatotic liver disease (MASLD) through microbiota‐host interaction. However, the beneficial role of commensal mycobiota in MASLD progression remains poorly understood.
Shuping Qiao   +11 more
wiley   +1 more source

Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis

open access: yesHaematologica, 2010
Background Residual chronic myeloid leukemia disease following imatinib treatment has been attributed to the presence of quiescent leukemic stem cells intrinsically resistant to imatinib.
Fabrizio Vianello   +10 more
doaj   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

open access: yesAdvanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong   +5 more
wiley   +1 more source

Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling

open access: yesHaematologica, 2009
We examined the gene expression profiles of two independent cohorts of patients with acute myeloid leukemia [n=247 and n=214 (younger than or equal to 60 years)] to study the applicability of gene expression profiling as a single assay in prediction of ...
Roel G.W. Verhaak   +8 more
doaj   +1 more source

Acute myeloid leukemia: does sex matter? [PDF]

open access: yesLeukemia
Sex differences are increasingly recognized in the diagnosis and treatment of diseases. Biologically, the primary distinction between females and males is rooted in their sex chromosomes, XX in females and XY in males. While these chromosomal differences account for DNA-based variations, sex-related biological traits are complex and can be influenced ...
Jesse M. Tettero   +2 more
openaire   +3 more sources

Time‐Controlled Refrigerated Stem Cell Therapy Mitigates Scleroderma Fibrosis via Modulation of Mitochondrial Autophagy and Gut Metabolism

open access: yesAdvanced Science, EarlyView.
This study established an RT‐MSCs‐based therapeutic approach for scleroderma in mice. RT‐MSCs attenuated fibrosis by regulating mitochondrial autophagy and restored gut microbiota homeostasis. Metabolomic analyses confirmed recovery of key metabolites, and RT‐MSCs demonstrated favorable lesion targeting and safety profiles.
Xue Xia   +5 more
wiley   +1 more source

Radotinib inhibits mitosis entry in acute myeloid leukemia cells via suppression of Aurora kinase A expression

open access: yesTumor Biology, 2019
Aurora kinases play critical roles in regulating several processes pivotal for mitosis. Radotinib, which is approved in South Korea as a second-line treatment for chronic myeloid leukemia, inhibits the tyrosine kinase BCR-ABL and platelet-derived growth ...
Sook-Kyoung Heo   +10 more
doaj   +1 more source

Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient

open access: yesHematology Reports, 2014
Acute myeloid leukemia (AML) is a hematological malignancy of myeloid progenitor cells that disrupt normal hematopoiesis. Current chemotherapy regimens result in complete remission in many cases; however, there exists no standard efficacious therapy for ...
Harry Ross Powers   +4 more
doaj   +1 more source

Beyond CD30: Dual‐Targeting of Malignant and Regulatory T Cells by Brentuximab Vedotin Remodels the Lymphoma Microenvironment and Overcomes Resistance via BCL2 Inhibition in Mycosis Fungoides

open access: yesAdvanced Science, EarlyView.
Single‐cell RNA analyses of paired lesions from CD30+ mycosis fungoides patients demonstrate that brentuximab vedotin (BV) induces immunogenic cell death in both CD30+ and CD30− malignant T cells. BV also targets regulatory T cells and remodels tumor microenvironment, while resistance is driven by impaired IFN responses, drug efflux, and BCL2 ...
Yi Jiang   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy